447 related articles for article (PubMed ID: 18272184)
1. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.
Hung SH; Yeh CH; Huang HT; Wu P; Ho ML; Chen CH; Wang C; Chao D; Wang GJ
Life Sci; 2008 Mar; 82(11-12):561-9. PubMed ID: 18272184
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
Gimble JM; Robinson CE; Wu X; Kelly KA; Rodriguez BR; Kliewer SA; Lehmann JM; Morris DC
Mol Pharmacol; 1996 Nov; 50(5):1087-94. PubMed ID: 8913339
[TBL] [Abstract][Full Text] [Related]
3. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
Lahiri S; Sen T; Palit G
Eur J Pharmacol; 2009 May; 609(1-3):118-25. PubMed ID: 19281808
[TBL] [Abstract][Full Text] [Related]
4. Use of differentiating adult stem cells (marrow stromal cells) to identify new downstream target genes for transcription factors.
Ylöstalo J; Smith JR; Pochampally RR; Matz R; Sekiya I; Larson BL; Vuoristo JT; Prockop DJ
Stem Cells; 2006 Mar; 24(3):642-52. PubMed ID: 16439615
[TBL] [Abstract][Full Text] [Related]
5. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism.
Kim WK; Meliton V; Amantea CM; Hahn TJ; Parhami F
J Bone Miner Res; 2007 Nov; 22(11):1711-9. PubMed ID: 17638575
[TBL] [Abstract][Full Text] [Related]
6. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone.
Bruedigam C; Eijken M; Koedam M; van de Peppel J; Drabek K; Chiba H; van Leeuwen JP
Stem Cells; 2010 May; 28(5):916-27. PubMed ID: 20213769
[TBL] [Abstract][Full Text] [Related]
7. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells.
Muruganandan S; Roman AA; Sinal CJ
J Bone Miner Res; 2010 Feb; 25(2):222-34. PubMed ID: 19929432
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway.
Kawai M; Namba N; Mushiake S; Etani Y; Nishimura R; Makishima M; Ozono K
J Mol Endocrinol; 2007 Feb; 38(1-2):19-34. PubMed ID: 17242167
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.
Ohama Y; Harada T; Iwabe T; Taniguchi F; Takenaka Y; Terakawa N
Fertil Steril; 2008 Feb; 89(2):311-7. PubMed ID: 17555752
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Mrówka P; Głodkowska E; Młynarczuk-Biały I; Biały L; Kuckelkorn U; Nowis D; Makowski M; Legat M; Gołab J
Acta Biochim Pol; 2008; 55(1):75-84. PubMed ID: 18327303
[TBL] [Abstract][Full Text] [Related]
11. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
13. Effect of troglitazone on CYP1A1 induction.
Kim HG; Han EH; Jeong HG
Toxicology; 2008 Apr; 246(2-3):166-71. PubMed ID: 18308446
[TBL] [Abstract][Full Text] [Related]
14. Very low density lipoprotein receptor promotes adipocyte differentiation and mediates the proadipogenic effect of peroxisome proliferator-activated receptor gamma agonists.
Tao H; Hajri T
Biochem Pharmacol; 2011 Dec; 82(12):1950-62. PubMed ID: 21924248
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway.
Tanaka H; Makino Y; Miura T; Hirano F; Okamoto K; Komura K; Sato Y; Makino I
J Immunol; 1996 Feb; 156(4):1601-8. PubMed ID: 8568266
[TBL] [Abstract][Full Text] [Related]
16. Mechanical loading and delta12prostaglandin J2 induce bone morphogenetic protein-2, peroxisome proliferator-activated receptor gamma-1, and bone nodule formation in an osteoblastic cell line.
Siddhivarn C; Banes A; Champagne C; Riché EL; Weerapradist W; Offenbacher S
J Periodontal Res; 2007 Oct; 42(5):383-92. PubMed ID: 17760815
[TBL] [Abstract][Full Text] [Related]
17. Global gene profiling reveals novel glucocorticoid induced changes in gene expression of human lens epithelial cells.
Gupta V; Galante A; Soteropoulos P; Guo S; Wagner BJ
Mol Vis; 2005 Nov; 11():1018-40. PubMed ID: 16319822
[TBL] [Abstract][Full Text] [Related]
18. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
Yamamoto A; Kakuta H; Sugimoto Y
Int Immunopharmacol; 2014 Sep; 22(1):204-8. PubMed ID: 24975659
[TBL] [Abstract][Full Text] [Related]
19. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
20. Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells.
Zhou H; Yang X; Wang N; Zhang Y; Cai G
Mol Cell Endocrinol; 2007 May; 270(1-2):17-22. PubMed ID: 17363141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
